6/28/23, 11:16 PM MOPETT Pathway Feedback Search Clinical Topics Home Studies MOPETT MOPETT Disease Disease Deep vein thrombosis Pulmonary embolism Trial question What is the role of low-dose thrombolysis in patients with moderate PE? Study design Single center Open label RCT Population Characteristics of study participants 55.0% female N = 121 45.0% male 121 patients (66 female, 55 male) Inclusion criteria: patients with moderate PE Key exclusion criteria: eligibility for full-dose thrombolysi,contraindication to unfractionated or low- molecular-weight heparin, severe thrombocytopenia, major bleeding within < 2 months requiring transfusion, surgery or major trauma within < 2 weeks, brain mass Interventions N=61 thrombolysis ("safe dose" of tPA plus anticoagulation) N=60 control (anticoagulation alone) Primary outcome Pulmonary hypertension at 28 months https://web.pathway.md/studies/recAd1q4kvXPIXnl0 1/2 6/28/23, 11:16 PM MOPETT Pathway 57.0 % 57 42.8 % 28.5 % Significant decrease 16 14.3 % NNT = 2 0.0 % Thrombolysis Control Significant decrease in pulmonary hypertension at 28 months (16% vs. 57%; RR 0.28, 95% CI 0.11 to 0.45) Secondary outcomes Significant decrease in pulmonary hypertension or recurrent PE (16% vs. 63%; RR 0.25, 95% CI 0.1 to 0.4) Significant decrease in death or recurrent PE (1.6% vs. 10%; RR 0.16, 95% CI 0 to 0.32) Significant decrease in duration of hospitalization (2.2 vs. 4.9; AD -2.7, 95% CI -4.3 to -1.1) Conclusion In patients with moderate PE, thrombolysis were superior to control with respect to pulmonary hypertension at 28 months. Reference Sharifi M, Bay C, Skrocki L et al. Moderate pulmonary embolism treated with thrombolysis (from the "MOPETT" Trial). Am J Cardiol. 2013 Jan 15;111(2):273-7. Open reference URL https://web.pathway.md/studies/recAd1q4kvXPIXnl0 2/2